Stefan Lethagen (Former)
11 – 20 of 77
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
- 2010
-
Mark
The impact of bleeding history, von Willebrand factor and PFA-100 (R) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD
(
- Contribution to journal › Article
-
Mark
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD
(
- Contribution to journal › Article
- 2008
-
Mark
Asn1421Lys mutation in the glycoprotein Ib binding domain impairs - ristocetin and botrocetin - mediated binding of von Willebrand factor to platelets
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.116-116(
- Contribution to journal › Published meeting abstract
-
Mark
Distribution of von Willebrand factor levels in young women with and without bleeding symptoms. Influence of ABO blood group and promoter haplotypes
(
- Contribution to journal › Article
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD)
(
- Contribution to journal › Article
-
Mark
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
(
- Contribution to journal › Article
-
Mark
Patients' and their family members' understanding of the genetics of type 1 von Willebrand disease.
(
- Contribution to journal › Letter
-
Mark
N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
(
- Contribution to journal › Article